<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/222864-aqueous-pharmaceutical-preparation-in-the-form-of-a-solution by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 07:29:02 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 222864:&quot;AQUEOUS PHARMACEUTICAL PREPARATION IN THE FORM OF A SOLUTION&quot;</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">&quot;AQUEOUS PHARMACEUTICAL PREPARATION IN THE FORM OF A SOLUTION&quot;</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>The present invention relates to pharmaceutical preparations in the form of aqueous solutions for the production of propellant-free aerosols.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>The present invention relates to pharmaceutical<br>
preparations in the form of aqueous solutions for the<br>
production of propellant-free aerosols for inhalation.<br>
In the last 20 years, the use of dosage aerosols has<br>
become a strong part of the therapy of obstructive lung<br>
diseases, especially asthma. Usually, fluorochlorohydrocarbons<br>
are used as propellant gases. Following the<br>
recognition of the ozone damaging potential of these<br>
propellant gases, attempts to develop alternatives have<br>
increased. One alternative is the development of<br>
nebulisers, where aqueous solutions of pharmacologically<br>
active substance are sprayed under high pressure so that a<br>
mist of inhalable particles results. The advantage of<br>
these nebulisers is that they completely dispense with the<br>
use of propellant gases.<br>
Such nebulisers are, for example, described in PCT Patent<br>
Application W091/14468, herein incorporated by reference.<br>
With the nebulisers described here, active ingredients<br>
solutions in defined volumes are sprayed through small<br>
jets under high pressure, so that inhalable aerosols with<br>
a mean particle size of between 3 and 10 micrometers<br>
result. A further developed embodiment of the<br>
aforementioned nebuliser is described in PCT/EP96/04351.<br>
The nebuliser portrayed in Figure 6 carries the trade mark<br>
RespimatÂ®.<br>
Usually, Pharmaceuticals intended for inhalation are<br>
dissolved in an aqueous or ethanolic solution, and<br>
according to the solution characteristics of the active<br>
substances, solvent mixtures of water and ethanol may also<br>
be suitable.<br>
Other components of the solvent are, apart from water<br>
and/or ethanol, optionally other cosolvents, and also the<br>
pharmaceutical preparation may also additionally contain<br>
flavourings and other pharmacological additives. Examples<br>
of cosolvents are those which contain hydroxyl groups or<br>
other polar groups, for example alcohols - especially<br>
isopropylalcohol, glycols - especially propyleneglycol,<br>
polyethyleneglycol, polypropyleneglycol, glycolether,<br>
glycerol, polyoxyethylene alcohols and polyoxyethylene<br>
fatty acid esters. Cosolvents are suitable for increasing<br>
the solubility of adjuvant materials and, if necessary,<br>
active ingredients.<br>
The proportion of dissolved pharmaceutical in the finished<br>
pharmaceutical preparation is between 0.001 and 30% -<br>
preferably between 0.05 and 3%, especially 0.01 to 2%.<br>
The maximum concentration of pharmaceutical is dependent<br>
on the solubility in solvent and on the dosage required to<br>
achieve the desired therapeutical effect.<br>
All substances which are suitable for application by<br>
inhalation and which are soluble in the specified solvent<br>
can be used as Pharmaceuticals in the new preparations.<br>
Pharmaceuticals for the treatment of diseases of the<br>
respiratory passages are of especial interest.<br>
Therefore, of especial interest are betamimetics,<br>
anticholinergics, antiallergics, antihistamines and<br>
steroids, as well as combinations of these active<br>
ingredients.<br>
It was found, in a series of examinations, that the<br>
nebuliser described above can feature spraying anomalies<br>
when using aqueous pharmaceutical solutions (generally,<br>
double distilled or demineralised (ion exchanged) water is<br>
used as a solvent). These spraying anomalies represent an<br>
alteration of the spraying pattern of the aerosol, with<br>
the consequence that in extreme cases an exact dose can no<br>
longer be guaranteed to the patient as a result of the<br>
altered mean droplet size distribution (alteration to the<br>
lung accessible part of the aerosol). These spraying<br>
anomalies especially occur when the nebuliser is used at<br>
intervals, for example with breaks of approximately 3 or<br>
more days between utilisation. It is possible that these<br>
spraying anomalies, which in extreme cases can lead to a<br>
dysfunction of the nebuliser, are as a result of<br>
microscopic deposits in the area of the jet opening.<br>
Surprisingly, it was discovered that these spraying<br>
anomalies no longer occur when the aqueous pharmaceutical<br>
preparations which are to be sprayed contain a defined<br>
effective quantity of a complexing agent, especially of<br>
EDTA (ethylenediamine tetraacetic acid) or salts thereof.<br>
The aqueous pharmaceutical preparations according to the<br>
invention contain water as a solvent, but if necessary<br>
ethanol can be added to increase the solubility up to 70%<br>
(by volume), preferably between 30 and 60% (by volume).<br>
Other pharmacological adjuvants such as preservatives,<br>
especially benzalkonium chloride, can be added. The<br>
preferred quantity of preservative, especially<br>
benzalkonium chloride, is between 8 and 12 mg/100 ml<br>
solution.<br>
Suitable complexing agents are those which are<br>
pharmacologically acceptable, especially those which are<br>
already approved by medical regulating authorities. EDTA,<br>
nitrilotriacetic acid, citric acid and ascorbic acid and<br>
their salts are especially suitable. The disodium salt of<br>
ethylenediamtetraacetic acid is especially preferred.<br>
The quantity of complexing agent is selected so that an<br>
effective quantity of complexing agent is added to prevent<br>
further occurrence of spraying anomalies.<br>
The effective quantity of the complexing agent Na-EDTA is<br>
between 10 and 1000 mg/100 ml solution, especially between<br>
10 and 100 mg/100 ml solution. The preferred range of the<br>
quantity of complexing agent is between 25 and<br>
75 mg/100 ml solution, especially between 25 and<br>
50 mg/100 ml solution.<br>
The following named compounds can principally be used as<br>
active ingredients, singly or in combination, in the<br>
aqueous pharmaceutical preparation according to the<br>
invention. In individual cases, it may be required to add<br>
a higher quantity of ethanol or a solution mediator to<br>
improve solubility.<br>
Tiotropium bromide, 3-[(hydroxydi-2-thienylacetyl)oxy]-<br>
8, 8-dimethyl-8-azoniabicyclo[3.2.1] oct-6-ene-bromide<br>
As betamimetics:<br>
Bambuterol Bitolterol Carbuterol Formoterol<br>
Clenbuterol Fenoterol Hexoprenaline Procaterol<br>
Ibuterol Pirbuterol Salmeterol Tulobuterol<br>
Reproterol Salbutamol Sulfonterol Terbutaline<br>
1-(2-Fluoro-4-hydroxyphenyl)-2-[4-(1-benzimidazolyl)-2-<br>
methyl-2-butylamino]ethanol,<br>
erythro-5'-hydroxy-8'-(l-hydroxy-2-isopropylaminobutyl)-<br>
2H-1,4-benzoxazin-3-(4H)-one,<br>
1-(4-Amino-3-chloro-5-trifluoromethylphenyl)-2-tert.-<br>
butyl-amino)ethanol,<br>
1-(4-Ethoxycarbonylamino-3-cyano-5-fluorophenyl)-2-(tert.-<br>
butylamino)ethanol.<br>
As anticholinergi.es:<br>
Ipratropium bromide<br>
Oxitropium bromide<br>
Trospium chloride<br>
N~P~fluoroethylene nortropine benzylate methobromide<br>
As steroids:<br>
Budesonide<br>
Beclometasone (or the 17,21-dipropionate)<br>
Dexamethasone-21-i sonicot inate<br>
Flunisolide<br>
As antiallergics:<br>
Disodium cromoglycate<br>
Nedocromil<br>
Epinastine<br>
Examples of steroids which can be used as active<br>
ingredients in the pharmaceutical preparations according<br>
to the invention:<br>
Seratrodast<br>
Pranlukast<br>
Butixocort<br>
Deflazacort<br>
Fluticasone<br>
Mometasone furoate<br>
Beclomethasone, Douglas<br>
Ciclometasone<br>
Fluocortin butyl<br>
Deflazacort<br>
Ciclometasone<br>
Prednicarbate<br>
Tixocortol-pivalate<br>
Mycophenolate mofetil<br>
Zileutone<br>
Budesonide<br>
Promedrol<br>
Tipredane<br>
Icomethasone enbutate<br>
Cloprednol<br>
Halometasone<br>
Alclometasone<br>
Alisactide<br>
Hydrocortisone-butyrate<br>
propionate<br>
Alclometasone-dipropionate<br>
Lotrisone<br>
Deprodone<br>
Methylprednisolone-<br>
Aceponate<br>
Moraetasone<br>
Hydrocort isone-aceponate<br>
Ulobetasol-propionate<br>
Triamcinolone<br>
Meprednisone<br>
Dexamethasone<br>
Medrysone<br>
Fluocinolone acetonide<br>
Deprodone Propionate<br>
Fluocinonide<br>
Difluprednate<br>
Dexamethasone isonicotinate<br>
Fluocortolone capronate<br>
Triamcinolone-Hexacetonide<br>
Formebolone<br>
Endrisone<br>
Halcinonide<br>
Clobetasol<br>
Diflorasone<br>
Amcinonide<br>
Cortivazol<br>
Fluodexane<br>
Budesonide<br>
Demetex<br>
Canesten-HC<br>
Fluticasone-propionate<br>
Halopredone-acetate<br>
Mometasone-furoate<br>
Mometasone<br>
Aminoglutethimide<br>
Hydrocort i sone<br>
Fluorometholone<br>
Betamethasone<br>
Fluclorolone acetonide<br>
Paramethasone-acetate<br>
Aristocort-diacetate<br>
Mazipredone<br>
Betamethasone valerate<br>
Beclomethasone-Dipropionate<br>
Formocortal<br>
Cloprednol<br>
Clobetasone<br>
Flunisolide<br>
Fluazacort<br>
Hydrocortisone-17-Butyrate<br>
Fluocortin<br>
Betamethasone Dipropionate<br>
Betamethasone adamantoate<br>
Trilostane<br>
Clobetasone<br>
Trimacinolon Benetonide<br>
9-ct-chloro-6-a-fluoro-ll-p-17-a-dihydroxy-16-a-methyl-3-<br>
oxo-1,4-androstadiene-17-p-carboxylic acid-methylester-17-<br>
propionate.<br>
Other especially suitable active ingredients for the<br>
production of aqueous pharmaceutical preparations for<br>
applications by inhalation are:<br>
p-Sympatico-mimetics;<br>
e.g. Fenoterol, Salbutamol, Formoterol, Terbutalin;<br>
Anticholinergics;<br>
e.g. Ipatropium, Oxitropium, Thiotropium;<br>
Steroids;<br>
e.g. Beclomethasone dipropionate, Budesonide, Flunisolide;<br>
Peptides;<br>
e.g. insulin;<br>
Pain killers;<br>
e.g. Fentanyl.<br>
It is obvious that those pharmacologically acceptable<br>
salts will be used which dissolve in the solvent according<br>
to the invention if necessary.<br>
In the following text, the advantage of the pharmaceutical<br>
preparation according to the invention will be explained<br>
more clearly with Examples.<br>
As a pharmaceutical solution, Ipratropium bromide solution<br>
(c = 333 mg/100 ml) with a pH value of 3.4, and the<br>
preservative benzalkonium chloride (c = 10 mg/100 ml) was<br>
used. The tested solutions either contained no EDTA or<br>
EDTA in a concentration of c = 0.1 mg, 1 mg, 50 mg and<br>
75 mg/100 ml as a disodium salt.<br>
Unused RespimatÂ® nebulisers were used for the test<br>
(technical data: volumes of the applied pharmaceutical<br>
preparation approximately 15 l, pressure approximately<br>
300 bar, 2 streams impacting from two jet openings of size<br>
5 x 8 Âµl. The operation mode for the test is set so that<br>
the units are used 5 times, are left to stand for 3 days,<br>
and then are used again 5 times, this pattern being<br>
repeated. 15 units were examined in each series of<br>
measurements, the results with regard to spray anomalies are shown in Table 1.<br>
Table 1<br>
(Table Removed)<br><br>
Formulation Examples (for Fenoterol and Ipatropium bromide)<br>
(Table Removed)<br><br>
In analogy to the above Examples, the following solutions were produced.<br>
(Table Removed)<br>
In the form of the disodium salt<br>
A concentration range from 10 mg to 20,000 mg/100 ml is<br>
conceivable for the active ingredients, depending on the<br>
dose per operation and their solubility. The specified<br>
doses are calculated based on a therapeutically effective<br>
single dose of approximately 12 microlitres per operation.<br>
The active ingredient concentrations of the pharmaceutical<br>
preparations can alter when the volume of the individual<br>
dose is altered.<br>
The concentration range for the complexing agents (for<br>
example DiNa-EDTA) is between 10 and 1000 mg/100 ml<br>
(dependent on the pH value of the solution). The<br>
preferred range is between 25 mg and 100 mg/100 ml.<br>
The quantity of benzalkonium chloride should be in the<br>
range of 8 to 12 mg/100 ml.<br>
The solutions are set to a pH of 3.2 to 3.4 with 0.1 or IN<br>
HCl. All concentrations relate to 100 ml of finished<br>
active ingredient solution.<br><br><br><br><br>
WE CLAIMS:<br>
1. An aqueous pharmaceutical preparation in the form of<br>
a solution for the production of propellant-free aerosols<br>
for inhalation comprising a pharmacologically active<br>
ingredient, characterised in that the pharmaceutical<br>
preparation contains a complexing agent.<br>
2. A pharmaceutical preparation according to claim 1,<br>
characterised in that the active ingredient is intended<br>
for application by inhalation, especially for the<br>
treatment of respiratory passage diseases.<br>
3. A pharmaceutical preparation according to claim 2,<br>
characterised in that the active ingredient is selected<br>
from the group betamimetics, anticholinergics,<br>
antiallergics and/or antihistamines.<br>
4. A pharmaceutical preparation according to claims 1, 2<br>
or 3, characterised in that the active ingredient is<br>
selected from the group<br>
Fenotrol, Ipatropium bromide, Berotec, Atrovent, Berodual,<br>
Salbutamol, Combivent, Ba 679 Br, BEA 2108 Br, Oxivent.<br>
5. A pharmaceutical preparation according to any one of<br>
claims 1 to 4, characterised in that the complexing agent<br>
is nitrilotriacetic acid, citric acid, ascorbic acid or<br>
salts thereof.<br>
6. A pharmaceutical preparation according to any one of<br>
claims 1 to 4, characterised in that the complexing agent<br>
is EDTA or a salt thereof.<br>
7. A pharmaceutical preparation according to any one of<br>
claims 1 to 6, characterised in that the concentration of<br>
the complexing agent is between 10 and 100 mg/100 ml<br>
solution.<br>
8. A pharmaceutical preparation according to claim 7<br>
characterised in that the concentration of the complex<br>
former is between 25 and 75 mg/100 ml solution.<br>
9. A pharmaceutical preparation according to one of<br>
claims 1 to 8, characterised in that the adjuvant is a<br>
preservative.<br>
10. A pharmaceutical preparation according to claim 9,<br>
characterised in that the preservative is Benzalkonium<br>
chloride.<br>
11. A pharmaceutical preparation according to any one of<br>
the previous claims, characterised in that the<br>
pharmaceutical preparation contains up to 70% (by volume)<br>
ethanol.<br>
12. A pharmaceutical preparation according to one of the<br>
previous claims, characterised in that it contains the<br>
active ingredient in a concentration of 0.001 to<br>
2 g/100 ml solution.<br>
13. A pharmaceutical preparation according to any one of<br>
the previous claims, characterised in that it contains<br>
pharmacologically acceptable adjuvant and flavouring<br>
substances.<br>
14. The use of aqueous pharmaceutical preparations in the<br>
production of propellant-free aerosols for inhalation,<br>
characterised in that the pharmaceutical preparations<br>
contain a complexing agent.<br>
15. The use according to claim 14, characterised in that<br>
the active ingredient is selected from the group<br>
Betamimetics, Anticholinergics, Antiallergics and/or<br>
antihistamines.<br>
16. The use according to claim 14 or 15, characterised in<br>
that the active ingredient is selected from the group<br>
Fenotrol, Ipatropium bromide, Berotec, Atrovent, Berodual,<br>
Salbutamol, Combivent, Ba 679 Br, BEA 2108 Br, Oxivent.<br>
17. The use according to any one of claims 14 to 16,<br>
characterised in that the complexing agent is<br>
nitriloacetic acid, citric acid, ascorbic acid or a salt<br>
thereof.<br>
18. The use according to any one of claims 14 to 16,<br>
characterised in that the complexing agent is EDTA or a<br>
salt thereof.<br>
19. The use according to claim 18, characterised in that<br>
the concentration of the complexing agent is between 25<br>
and 75 mg.<br>
20. The use according to any one of claims 14 to 19,<br>
characterised in that the pharmaceutical preparation<br>
contains up to 70% (by volume) ethanol.<br>
21. The use according to any one of claims 14 to 20,<br>
characterised in that the pharmaceutical preparation<br>
contains active ingredient in a concentration of 0.001 to<br>
2 g/100 ml solution.<br>
22. An aqueous pharmaceutical preparation substantially as herein described with<br>
reference to the foregoing examples.<br></td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzYzNC1ERUwtMTk5Ny1BYnN0cmFjdC0oMjYtMDMtMjAwOCkucGRm" target="_blank" style="word-wrap:break-word;">3634-DEL-1997-Abstract-(26-03-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzYzNC1kZWwtMTk5Ny1hYnN0cmFjdC5wZGY=" target="_blank" style="word-wrap:break-word;">3634-del-1997-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzYzNC1ERUwtMTk5Ny1DbGFpbXMtKDI2LTAzLTIwMDgpLnBkZg==" target="_blank" style="word-wrap:break-word;">3634-DEL-1997-Claims-(26-03-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzYzNC1kZWwtMTk5Ny1jbGFpbXMucGRm" target="_blank" style="word-wrap:break-word;">3634-del-1997-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzYzNC1ERUwtMTk5Ny1Db3JyZXNwb25kZW5jZS1PdGhlcnMtKDI2LTAzLTIwMDgpLnBkZg==" target="_blank" style="word-wrap:break-word;">3634-DEL-1997-Correspondence-Others-(26-03-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzYzNC1kZWwtMTk5Ny1jb3JyZXNwb25kZW5jZS1vdGhlcnMucGRm" target="_blank" style="word-wrap:break-word;">3634-del-1997-correspondence-others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzYzNC1ERUwtMTk5Ny1EZXNjcmlwdGlvbiAoQ29tcGxldGUpLSgyNi0wMy0yMDA4KS5wZGY=" target="_blank" style="word-wrap:break-word;">3634-DEL-1997-Description (Complete)-(26-03-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzYzNC1kZWwtMTk5Ny1kZXNjcmlwdGlvbiAoY29tcGxldGUpLnBkZg==" target="_blank" style="word-wrap:break-word;">3634-del-1997-description (complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzYzNC1ERUwtMTk5Ny1Gb3JtLTEtKDI2LTAzLTIwMDgpLnBkZg==" target="_blank" style="word-wrap:break-word;">3634-DEL-1997-Form-1-(26-03-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzYzNC1kZWwtMTk5Ny1mb3JtLTEucGRm" target="_blank" style="word-wrap:break-word;">3634-del-1997-form-1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzYzNC1kZWwtMTk5Ny1mb3JtLTE4LnBkZg==" target="_blank" style="word-wrap:break-word;">3634-del-1997-form-18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzYzNC1ERUwtMTk5Ny1Gb3JtLTItKDI2LTAzLTIwMDgpLnBkZg==" target="_blank" style="word-wrap:break-word;">3634-DEL-1997-Form-2-(26-03-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzYzNC1kZWwtMTk5Ny1mb3JtLTIucGRm" target="_blank" style="word-wrap:break-word;">3634-del-1997-form-2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzYzNC1kZWwtMTk5Ny1mb3JtLTI5LnBkZg==" target="_blank" style="word-wrap:break-word;">3634-del-1997-form-29.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzYzNC1ERUwtMTk5Ny1Gb3JtLTMtKDI2LTAzLTIwMDgpLnBkZg==" target="_blank" style="word-wrap:break-word;">3634-DEL-1997-Form-3-(26-03-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzYzNC1kZWwtMTk5Ny1mb3JtLTQucGRm" target="_blank" style="word-wrap:break-word;">3634-del-1997-form-4.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzYzNC1kZWwtMTk5Ny1mb3JtLTYucGRm" target="_blank" style="word-wrap:break-word;">3634-del-1997-form-6.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzYzNC1ERUwtMTk5Ny1HUEEtKDI2LTAzLTIwMDgpLnBkZg==" target="_blank" style="word-wrap:break-word;">3634-DEL-1997-GPA-(26-03-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzYzNC1kZWwtMTk5Ny1ncGEucGRm" target="_blank" style="word-wrap:break-word;">3634-del-1997-gpa.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzYzNC1ERUwtMTk5Ny1QZXRpdGlvbi0xMzctKDI2LTAzLTIwMDgpLnBkZg==" target="_blank" style="word-wrap:break-word;">3634-DEL-1997-Petition-137-(26-03-2008).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzYzNC1ERUwtMTk5Ny1QZXRpdGlvbi0xMzgtKDI2LTAzLTIwMDgpLnBkZg==" target="_blank" style="word-wrap:break-word;">3634-DEL-1997-Petition-138-(26-03-2008).pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="222863-a-vaccine.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="222865-a-synthetic-polynucleotides-encoding-two-or-more-immunogenic-hiv-polypeptides.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>222864</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>3634/DEL/1997</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>37/2008</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>12-Sep-2008</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>27-Aug-2008</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>16-Dec-1997</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>BOEHRINGER INGELHEIM KG.</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>D-55216 INGELHEIM AM RHEIN, GERMANY.</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>DR. BERNHARD FREUND</td>
											<td>KARL-DOMDEY-STR.28, D-55435 GAU-ALGESHEIM, GERMANY.</td>
										</tr>
										<tr>
											<td>2</td>
											<td>DR. BERND ZIERENBERG</td>
											<td>GOETHESTR. 1 D-55411 BINGEN AM RHEIN, GERMANY.</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>A61K</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>N/A</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td></td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>196 53 969.2</td>
									<td>1996-12-20</td>
								    <td>Germany</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/222864-aqueous-pharmaceutical-preparation-in-the-form-of-a-solution by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 07:29:03 GMT -->
</html>
